What do systematic reviews say?

Gene therapy vs no gene therapy control

Gene therapy showed no clear difference in amputation‐free survival compared with no gene therapy control (moderate certainty).

• Gene therapy for peripheral arterial disease 2018 · Cochrane Headline outcomes only
  OR 1.68 [0.75, 3.76]
  4 studies · 756 participants
  Moderate

Gene therapy vs no gene therapy control

Gene therapy may leads to higher ulcer healing compared with no gene therapy control (low certainty).

• Gene therapy for peripheral arterial disease 2018 · Cochrane Headline outcomes only
  OR 2.16 [1.02, 4.59]
  5 studies · 238 participants
  Low

Gene therapy vs no gene therapy control

• Gene therapy for peripheral arterial disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 699 participants
  Very low

Gene therapy vs no gene therapy control

Gene therapy showed no clear difference in amputation (above‐ankle amputation of the index limb) compared with no gene therapy control (moderate certainty).

• Gene therapy for peripheral arterial disease 2018 · Cochrane Headline outcomes only
  OR 1.06 [0.77, 1.46]
  11 studies · 1336 participants
  Moderate

Gene therapy vs no gene therapy control

Gene therapy showed no clear difference in all‐cause mortality compared with no gene therapy control (moderate certainty).

• Gene therapy for peripheral arterial disease 2018 · Cochrane Headline outcomes only
  OR 0.93 [0.66, 1.31]
  12 studies · 1685 participants
  Moderate

Gene therapy vs no gene therapy control

• Gene therapy for peripheral arterial disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 125 participants
  Low

Gene therapy vs no gene therapy control

• Gene therapy for peripheral arterial disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 152 participants
  Very low

Any growth factor vs Placebo or no active treatment

Growth factors showed no clear difference in major limb amputation ( compared with placebo or no therapy (moderate certainty).

• Growth factors for angiogenesis in peripheral arterial disease 2017 · Cochrane Headline outcomes only
  OR 0.99 [0.71, 1.38]
  10 studies · 1075 participants
  Moderate

Any growth factor vs Placebo or no active treatment

Growth factors may leads to lower any limb amputation ( compared with placebo or no therapy (low certainty).

• Growth factors for angiogenesis in peripheral arterial disease 2017 · Cochrane Headline outcomes only
  OR 0.56 [0.31, 0.99]
  6 studies · 415 participants
  Low

Any growth factor vs Placebo or no active treatment

Growth factors showed no clear difference in death ( compared with placebo or no therapy (moderate certainty).

• Growth factors for angiogenesis in peripheral arterial disease 2017 · Cochrane Headline outcomes only
  OR 0.99 [0.69, 1.41]
  12 studies · 1371 participants
  Moderate

Any growth factor vs Placebo or no active treatment

Growth factors showed no clear difference in serious adverse events ( compared with placebo or no therapy (moderate certainty).

• Growth factors for angiogenesis in peripheral arterial disease 2017 · Cochrane Headline outcomes only
  OR 1.09 [0.79, 1.5]
  13 studies · 1411 participants
  Moderate

Any growth factor vs Placebo or no active treatment

Growth factors showed no clear difference in any adverse event ( compared with placebo or no therapy (moderate certainty).

• Growth factors for angiogenesis in peripheral arterial disease 2017 · Cochrane Headline outcomes only
  OR 1.1 [0.73, 1.64]
  13 studies · 1411 participants
  Moderate